ID: ALA14210

Max Phase: Preclinical

Molecular Formula: C11H14N2

Molecular Weight: 174.25

Molecule Type: Small molecule

Representations

Synonyms (1): Phenyzoline
Synonyms from Alternative Forms(1):

Canonical SMILES:  c1ccc(CCC2=NCCN2)cc1

Standard InChI:  InChI=1S/C11H14N2/c1-2-4-10(5-3-1)6-7-11-12-8-9-13-11/h1-5H,6-9H2,(H,12,13)

Standard InChI Key:  CPMMXSDLEOJRHI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 174.25

Molecular Weight (Monoisotopic): 174.1157

AlogP: 1.62

#Rotatable Bonds: 3

Polar Surface Area: 24.39

Molecular Species: BASE

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 10.76

CX LogP: 1.65

CX LogD: -0.72

Aromatic Rings: 1

Heavy Atoms: 13

QED Weighted: 0.74

Np Likeness Score: -0.09

References

1. Baurin N, Vangrevelinghe E, Morin-Allory L, Mérour JY, Renard P, Payard M, Guillaumet G, Marot C..  (2000)  3D-QSAR CoMFA study on imidazolinergic I(2) ligands: a significant model through a combined exploration of structural diversity and methodology.,  43  (6): [PMID:10737743] [10.1021/jm991124t]

2. Gentili F, Bousquet P, Brasili L, Dontenwill M, Feldman J, Ghelfi F, Giannella M, Piergentili A, Quaglia W, Pigini M..  (2003)  Imidazoline binding sites (IBS) profile modulation: key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues.,  46  (11): [PMID:12747788] [10.1021/jm021113r]

3. Glennon RA, Grella B, Tyacke RJ, Lau A, Westaway J, Hudson AL..  (2004)  Binding of an imidazopyridoindole at imidazoline I2 receptors.,  14  (2): [PMID:14698196] [10.1016/j.bmcl.2003.09.092]

4. Gentili F, Cardinaletti C, Vesprini C, Ghelfi F, Farande A, Giannella M, Piergentili A, Quaglia W, Mattioli L, Perfumi M, Hudson A, Pigini M..  (2008)  Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions.,  51  (16): [PMID:18661965] [10.1021/jm800400k]

5. Mammoli V, Bonifazi A, Del Bello F, Diamanti E, Giannella M, Hudson AL, Mattioli L, Perfumi M, Piergentili A, Quaglia W, Titomanlio F, Pigini M..  (2012)  Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.,  20  (7): [PMID:22370341] [10.1016/j.bmc.2012.02.016]

6. Nicolotti O, Carotti A, Carrieri A, Pigini M, Gentili F, Brasili L, Giannella M, Quaglia W, Piergentili A, Bousquet P, Dontenwill M.  (2004)  Alpha2-Adrenergic Receptors in Intestinal Epithelial Cells: Mechanisms of Signaling, Role, and Regulation,  13  (3): [10.1007/s00044-004-0023-9]

7. Vucicevic J, Srdic-Rajic T, Pieroni M, Laurila JM, Perovic V, Tassini S, Azzali E, Costantino G, Glisic S, Agbaba D, Scheinin M, Nikolic K, Radi M, Veljkovic N..  (2016)  A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.,  24  (14): [PMID:27265687] [10.1016/j.bmc.2016.05.043]

Source

Source(1):

• Scientific Literature